Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
product portfolio
Biotech
Biogen inks $357M option deal for TMS' stroke drug
Biogen signed an option deal worth up to $357 million for TMS’ stroke treatment currently being tested in a placebo-controlled phase 2 study in Japan.
Conor Hale
Jun 7, 2018 10:05am
LivaNova strikes $250M deal to buy TandemLife
Feb 16, 2018 7:40am
Glooko, Novo Nordisk unveil joint diabetes management app
Jul 14, 2017 7:56am